• Skip to main content
  • Skip to navigation
Site name
Site name
Mast navigation
  • Become a member
  • Sign In
Search our site
Menu
Close menu
  • Home
  • News
  • Bioprocessing
  • QA
  • Topics
    • Back to parent navigation item
    • Topics
    • Analytical and bioanalysis
    • Bioprocessing and biomanufacturing
    • Quality, microbiology and contamination control
    • Regulation and compliance
    • Formulation and drug delivery
    • Packaging, containers and labelling
    • Digital and Pharma 4.0
  • Webinars
  • Reports
  • Publications
  • Future of Bio/Pharma 2026
  • Knowledge Hub
  • Home
  • News
  • Bioprocessing
  • QA
  • Topics
      • Analytical and bioanalysis
      • Bioprocessing and biomanufacturing
      • Quality, microbiology and contamination control
      • Regulation and compliance
      • Formulation and drug delivery
      • Packaging, containers and labelling
      • Digital and Pharma 4.0
    • jakarta-march-united-drug-fda
      FDA seeks feedback on new framework for rare disease drug development
    • AstraZeneca logo
      AstraZeneca commits $2bn to advance ADC combination medicines for cancer
    • novo nordisk logo
      Novo Nordisk tightens obesity market focus with ‘Novo’ name change
  • Webinars
  • Reports
  • Publications
  • Future of Bio/Pharma 2026
  • Knowledge Hub
  • More navigation items

Accelerating consistent, stable cell line development with targeted integration: References

2026-04-10T19:27:00+01:00

  • No comments

References and support materials for ”Accelerating consistent, stable cell line development with targeted integration”

 

References 

  1. Zalma V, et al. CHO Cells For Virus-Like Particle And Subunit Vaccine Manufacturing. Vaccine. 2024;42: 2530-2542.  

  1. Tihanyi B, Nyitray L. Recent Advances In CHO Cell Line Development For Recombinant Protein Production. Drug Discovery Today: Technologies. 2020;38: 25-34. 

  1. WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™ to Accelerate Biologics Development with High Titer and Superior Stability. [Internet] WuXI Biologics. 2025. Available from: https://www.wuxibiologics.com/press-release/wuxi-biologics-launches-wuxia4-targeted-integration-cell-line-platform-truesite-ti-accelerate-biologics-development-with-high-titer-and-superior-stability/ 

  1. McGovern ĀT, Salisbury C, Nyberg G. The Pandemic and Resilience for the Future: AccBio 2021. Biotechnol. Prog. 2022;38:e3207.  

 

  • No comments

No comments yet

You're not signed in.

Only registered users can comment on this article.

Sign in Register

Partner content

  • Shimadzu
    Whitepaper

    A software‑supported, AI‑assisted workflow for optimising LC gradient methods

    2026-01-15T11:44:00

    Sponsored by Shimadzu, Dr. Schad

  • CTA Image
    Article

    Selecting the right qPCR workflow strategy: task-based vs. full automation

    2026-06-01T08:21:00

    Sponsored by Gilson

  • trade show concept
    News

    CPHI Americas 2026 returns to Philadelphia with AI, regulatory focus

    2026-04-30T10:47:00

    Sponsored by CPhI

  • AdobeStock_918235265
    Article

    Protecting oral therapies through an intrinsically enteric capsule

    2026-10-27T10:14:00

    Sponsored by Capsugel

  • 230607_USP-9349
    Webinar

    Risks of non-compliance: managing impurity control and challenges with reference materials

    2026-09-23T13:00:00

    Sponsored by USP

  • BioDuro Webinar
    Webinar

    Choosing the right crystal: solid form optimisation for pharmaceutical development

    2026-06-10T15:00:00

    Sponsored by BioDuro

  • Topics
  • Analytical and bioanalysis
  • Bioprocessing and biomanufacturing
  • Quality, microbiology and contamination control
  • Regulation and compliance
  • Formulation and drug delivery
  • Packaging, containers and labelling
  • Advertising & Editorial
  • Advertising opportunities
  • Media planner
  • Advisory board
  • Information for authors
  • Reuse policy
  • Information
  • About us
  • Company information
  • Careers
  • Terms and conditions
  • Privacy policy
  • Cookie policy
Leading the conversation in pharma manufacturing
Find us on social media:
  • Topics A-Z
  • Writers A-Z
  • © 2026 European Pharmaceutical Review

Site powered by Webvision Cloud